Andros Pharmaceuticals Co., Ltd. (6917) Stock Price & Analysis
6917 Stock Chart & Stats
- Day’s Range
- TWD 25.95 - TWD 30.10
- 52-Week Range
- TWD 20.00 - TWD 45.95
- Previous Close
- TWD 30.30
- Volume
- N/A
- Average Volume (3M)
- 351.21K
- Market Cap
- TWD 1.65B
- Enterprise Value
- N/A
- Total Cash (Recent Filing)
- TWD 333.82M
- Total Debt (Recent Filing)
- TWD 15.06M
- Price to Earnings (P/E)
- ―
- Beta
- 0.07
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
6917 FAQ
What was Andros Pharmaceuticals Co., Ltd.’s price range in the past 12 months?
What is Andros Pharmaceuticals Co., Ltd.’s market cap?
When is Andros Pharmaceuticals Co., Ltd.’s upcoming earnings report date?
Is Andros Pharmaceuticals Co., Ltd. overvalued?
Does Andros Pharmaceuticals Co., Ltd. pay dividends?
What is Andros Pharmaceuticals Co., Ltd.’s EPS estimate?
How many shares outstanding does Andros Pharmaceuticals Co., Ltd. have?
Which hedge fund is a major shareholder of Andros Pharmaceuticals Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Andros Pharmaceuticals Co., Ltd.
Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the advancement of novel drug delivery platform technologies. Its development pipeline features APC101, a metered-dose, quick-drying, film-forming spray undergoing Phase IIa clinical investigation for the management of pain linked to post-herpetic neuralgia. Also in development is APC201, an innovative topical anesthetic formulation currently in Phase I/II trials for Osteoarthritis treatment, alongside an siRNA (small interfering RNA) compound functioning as an antisense oligonucleotide and DNA candidate. In the preclinical phase, the company is advancing APC310 and APC501, both intended as anesthetics for intravenous catheter insertion and venipuncture. Another preclinical asset, APC401, is a specialized emulsified solution targeting post-surgical pain relief. Beyond its developmental programs, Andros Pharmaceuticals also provides LALP cream for dermal analgesic use, iMinos solution for treating Alopecia Androgenetica, and T4 endonuclease V. Established in 2008, the firm maintains its headquarters in Zhubei, Taiwan.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Ming-Wen Lee
- Employees
- 15
- Website
- www.andros.com.tw
- Address
- No. 22, Shengyi Road, Zhubei, TP, 30261, TW
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |
